Anaplastic Thyroid Carcinoma: Doxorubicin, hyperfractionated radiotherapy and surgery

Authors

  • J. Tennvall Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden
  • E. Tallroth Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden
  • A. El Hassan Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden
  • G. Lundell Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden
  • M. Åkerman Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden
  • A. Biörklund Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden
  • H. Blomgren Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden
  • T. Löwhagen Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden
  • G. Wallin Departments of Oncology, Cytodiagnostics, and Otorhinolaryngology, University Hospital, Lund, Sweden; Department of Oncology, Radiumhemmet, Sweden; Departments of Cytodiagnostics and Surgery, Karolinska Hospital, Stockholm, Sweden

DOI:

https://doi.org/10.3109/02841869009091794

Keywords:

Thyroid, anaplastic carcinoma, combined modality treatment, doxorubicin, hyperfractionated radiotherapy, surgery

Abstract

Sixteen consecutive patients with anaplastic carcinoma of the thyroid were prospectively treated according to a combined regimen consisting of hyperfractionated radiotherapy, doxorubicin and debulking surgery. The radiotherapy was preoperatively administered to a target dose of 30 Gy in 3 weeks, and postoperatively to an additional dose of 16 Gy in 1.5 weeks. Radiotherapy was administered twice daily, 5 days a week, with a target dose of 1 Gy per fraction and with a minimum interval of 6 hours. A dose of 20 mg doxorubicin was administered intravenously 1 to 2 hours before the first radiotherapy session every week. Debulking surgery was feasible in 9 patients. Local complete remission was achieved in 5 patients and 3 of these are still alive disease-free at 10, 30, and 30 months respectively after diagnosis. Only 6 patients succumbed to a local failure. This combination regimen was well tolerated despite the patients' high age and advanced disease.

Downloads

Download data is not yet available.

Downloads

Published

1990-01-01

How to Cite

Tennvall, J., Tallroth, E., El Hassan, A., Lundell, G., Åkerman, M., Biörklund, A., … Wallin, G. (1990). Anaplastic Thyroid Carcinoma: Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncologica, 29(8), 1025–1028. https://doi.org/10.3109/02841869009091794

Issue

Vol. 29 No. 8 (1990): Acta Oncologica

Section

Articles